Theodoros K. Tsakiridis

Hamilton, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Editorial expression of concern: Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.

Editorial expression of concern: Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.

Journal: Radiation oncology (London, England)

Published: July 06, 2026

Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).

Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).

Journal: The Prostate

Published: May 18, 2026

Case - Long-term management of oligo-progressive metastatic castrate sensitive prostate cancer with recurrence-directed radiotherapy.

Case - Long-term management of oligo-progressive metastatic castrate sensitive prostate cancer with recurrence-directed radiotherapy.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: December 17, 2025

Canagliflozin is a novel androgen receptor pathway inhibitor for castrate-sensitive and castrate-resistant prostate cancer.

Canagliflozin is a novel androgen receptor pathway inhibitor for castrate-sensitive and castrate-resistant prostate cancer.

Journal: Cancer letters

Published: October 06, 2025

HER2-specific synthetic antigen receptor T cell therapy synergizes with radiotherapy to provide improved antitumor efficacy in non-small cell lung cancer.

HER2-specific synthetic antigen receptor T cell therapy synergizes with radiotherapy to provide improved antitumor efficacy in non-small cell lung cancer.

Journal: Journal of leukocyte biology

Published: August 22, 2025

Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial.

Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial.

Journal: International journal of radiation oncology, biology, physics

Published: August 11, 2025

In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

Journal: The Prostate

Published: June 09, 2025

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: March 31, 2025

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH.

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH.

Journal: Cell metabolism

Published: March 26, 2025

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

Journal: The Prostate

Published: February 11, 2025

Geographic and Sociodemographic Disparities in Access to Radiation Therapy in Brazil: A Nationwide Cross-Sectional Study (2017-2022).

Geographic and Sociodemographic Disparities in Access to Radiation Therapy in Brazil: A Nationwide Cross-Sectional Study (2017-2022).

Journal: International journal of radiation oncology, biology, physics

Published: February 06, 2025

Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting A regional cohort analysis.

Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting A regional cohort analysis.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: October 17, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026